Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
19.02.2026 05:37
Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive
Should You Buy Shares of CRISPR Therapeutics in February?
18.02.2026 15:13
The company could finally be ready to deliver on years of promise.
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash
18.02.2026 09:35
Vertex has the revenue power to excel during any market environment.
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $591
17.02.2026 08:06
HC Wainwright & Co. analyst Andrew S. Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $518 to $591.
Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?
17.02.2026 05:21
Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.
Tracking Tweedy Browne Portfolio - Q4 2025 Update
16.02.2026 03:52
Tweedy Browneâs 13F portfolio rose to $1.24B in Q4 2025, with Ionis Pharma now the largest position at 15.74%. Read more about the portfolio here.
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story
15.02.2026 06:09
Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives Vertex exclusive global rights to a preclinical stage asset, expanding its pipeline beyond cystic fibrosis. The partnership focuses on autoimmune conditions where existing treatment options leave substantial unmet medical need. For investors watching Vertex at a share price of $491.47, this move...
CRISPR Therapeutics Advances Casgevy Rollout As Pipeline And Valuation Attract Attention
15.02.2026 00:22
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now extend to the majority of eligible patients in the U.S., with rollouts reaching Europe and the Middle East. The company highlights new pipeline moves in autoimmune diseases, oncology, and lipid disorders, supported by collaborations with Vertex Pharmaceuticals and Sirius Therapeutics. For you...
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
14.02.2026 14:06
Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex Pharmaceuticals’ (VRTX) new guidance for Casgevy “looks promising,” says the analyst, who adds that the setup for Crispr “appears even better than initially appreciated.”Valentine's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the mar
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays
13.02.2026 14:54
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […]
Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential
13.02.2026 09:19
Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $518
13.02.2026 07:46
HC Wainwright & Co. analyst Andrew S. Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $478 to $518.
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
13.02.2026 05:05
Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.
Sana Biotechnology: A Small, Speculative Play
13.02.2026 03:24
Sana Biotechnology, Inc. focuses on SC451 for type 1 diabetes as single-patient data validates its immune-evasion platform. Check out why SANA stock is a buy.
Vertex Pharmaceuticals Q4 Earnings Call Highlights
13.02.2026 02:07
Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),
Vertex Pharmaceuticals Incorporated 2025 Q4 - Results - Earnings Call Presentation
13.02.2026 01:39
2026-02-13. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q4 earnings call.
Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight
13.02.2026 00:14
Vertex Pharmaceuticals shares dipped 1.24% in after-hours trading Thursday despite reporting a 10% rise in fourth-quarter revenue to $3.19 billion.
Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect
11.02.2026 03:03
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Thursday afternoon. Here’s what you need to know.